SCHEMBL21156819

SCHEMBL21156819

Cn1c(=O)[nH]c2cc(C(=O)CBr)ccc21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 4/20 0.45
▸ GSK3B P49841 4/20 0.43
▸ HSD11B1 P28845 2/20 0.43
▸ MAOB P27338 1/20 0.41
▸ PTPN1 P18031 2/20 0.41
▸ HTR3A P46098 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ DAO P14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21156822 0.88 LMNA (0.46) LMNAGSK3BMAOBPTPN1HTR3A
SCHEMBL30593445 0.88 LMNA (0.46) LMNAGSK3BMAOBPTPN1HTR3A
SCHEMBL8546016 0.83 LMNA (0.44) LMNAMAPTHSD11B1MAOBHTR3A
SCHEMBL21156821 0.81 LMNA (0.51) LMNAMAPTHSD11B1MAOBHTR3A
SCHEMBL1759317 0.81 ALDH1A1 (0.52) LMNAMAPTHSD11B1ALDH1A1KDM4E
SCHEMBL29670373 0.81 ALDH1A1 (0.52) LMNAMAPTHSD11B1ALDH1A1KDM4E
SCHEMBL25184324 0.80 LMNA (0.50) LMNAMAPTHSD11B1MAOBHTR3A
SCHEMBL31473248 0.80 KDM4E (0.57) LMNAMAPTHSD11B1MAOBHTR3A
SCHEMBL4850384 0.80 MAOB (0.42) LMNAMAPTHSD11B1MAOBHTR3A
Hydrochloric Acid SCHEMBL31473354 0.79 KDM4E (0.55) LMNAMAPTHSD11B1MAOBHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-05-19 — — US disclosed
CN-116134035-B 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2025-03-11 — — CN disclosed
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION ICAHN SCHOOL MED MOUNT SINAI (US) 2024-05-30 — — US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 — — US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 — — US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 — — US disclosed
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS JANSSEN RESEARCH & DEVELOPMENT, LLC 2023-09-21 — — US disclosed
EP-3717475-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-07 — — EP disclosed
EP-3717475-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-07 — — EP disclosed
EP-4185588-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS Janssen Pharmaceutica NV (BE) 2023-05-31 — — EP disclosed
CN-116134035-A 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2023-05-16 — — CN disclosed
US-11547712-B2 Kinase inhibitor compounds and compositions and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-01-10 — — US disclosed
US-11547712-B2 Kinase inhibitor compounds and compositions and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-01-10 — — US disclosed
US-20210032601-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-04 — — US disclosed
US-20210032601-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-04 — — US disclosed
CN-111936490-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2020-11-13 — — CN disclosed
US-20200306257-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2020-10-01 — — US disclosed
US-20200306257-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2020-10-01 — — US disclosed
WO-2019136320-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2019-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306257-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE MAP3K20, MAP3K1, PACSIN2 LMNA 1766/4885MAPT 1065/4885GSK3B 105/4885
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION IAPP, DYRK1A, GLP1R LMNA 4087/4885MAPT 4232/4885GSK3B 110/4885
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition GLP1R, DYRK1A, DYRK1B LMNA 3568/4885MAPT 3692/4885GSK3B 146/4885
US-11547712-B2 Kinase inhibitor compounds and compositions and methods of use MAP3K20, MAP3K1, PACSIN2 LMNA 1766/4885MAPT 1065/4885GSK3B 105/4885
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition IAPP, GLP1R, GPR119 LMNA 4336/4885MAPT 4231/4885GSK3B 106/4885
US-20210032601-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION IAPP, GLP1R, GPR119 LMNA 4336/4885MAPT 4231/4885GSK3B 106/4885
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS SERPINC1, F11, TFPI2 LMNA 594/4885MAPT 3987/4885GSK3B 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback